Adaptive Phage Therapeutics to Present at the FDA and NIH Hosted Workshop on Science and Regulation of Bacteriophage Therapy

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that Robert Hopkins, MD, Chief Medical Officer, will present at the upcoming Science and Regulation of Bacteriophage Therapy Workshop, hosted by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) and National Institute of Allergy and Infectious Diseases (NIH/NIAID). The purpose of the workshop is to exchange information with the medical and scientific communities regarding regulatory and scientific issues related to recent therapeutic bacteriophage treatment advances. APT welcomes the FDA and NIH’s interest in bacteriophage (“phage”) therapies as a leading alternative to newer classes of antibiotics to combat the global rise of antimicrobial-resistant (AMR) bacterial infections.

Dr. Hopkins’ presentation will address Adaptive Phage Therapeutics’ approach to combating emerging antimicrobial resistance with an evergreen library of bacteriophage (PhageBank^™). The presentation will be held on Tuesday, August 31, 2021 at 12:20 pm ET.

In addition, Michele Wales, Ph.D., JD, APT’s Chief Legal Officer, will lead a breakout session focused on the patentability of phage therapeutics. Dr. Wales’ session will be held Monday, August 30, 2021 at 2:40 pm ET.

The Science and Regulation of Bacteriophage Therapy Workshop is a free and virtual event accessible by the public. To register, please visit this event’s registration page or find the event under the ‘News & Events’ page on the National Institute of Allergy and Infectious Diseases’ website.

Adaptive Phage Therapeutics, Inc.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been "fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.

APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.

APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

For more information, visit http://www.aphage.com.